EcoDrugPlus

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 4

Ensembl ID : ENSOMEG00000004240
Gene Symbol: CACNG4
3 Cross references
187 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 5

Ensembl ID : ENSOMEG00000008773
Gene Symbol: CACNG5
3 Cross references
184 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 5

Ensembl ID : ENSOMEG00000011415
Gene Symbol: CACNG5
3 Cross references
169 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 6

Ensembl ID : ENSOMEG00000011340
Gene Symbol: CACNG6
3 Cross references
176 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 7

Ensembl ID : ENSOMEG00000011308
Gene Symbol: CACNG7
3 Cross references
187 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 8

Ensembl ID : ENSOMEG00000011321
Gene Symbol: CACNG8
3 Cross references
153 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 A

Ensembl ID : ENSOMEG00000016125
Gene Symbol: CACNA1A
1 Cross references
186 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 B

Ensembl ID : ENSOMEG00000016220
Gene Symbol: CACNA1B
1 Cross references
218 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSOMEG00000006777
Gene Symbol: CACNA1D
2 Cross references
208 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSOMEG00000006312
Gene Symbol: CACNA1E
1 Cross references
207 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 G

Ensembl ID : ENSOMEG00000011059
Gene Symbol: CACNA1G
1 Cross references
196 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 H

Ensembl ID : ENSOMEG00000001935
Gene Symbol: CACNA1H
3 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).